Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes.
The Company’s science is targeting immune-excluded tumors, an identifiable, prevalent solid tumor phenotype. Incendia’s unique approach breaks down physical and biochemical barriers within the TME to enhance host immune cell infiltration into tumors and enable cancer therapeutics to reach their targets across a broad range of solid cancers. Incendia believes that there are multiple novel opportunities within the TME to target treatment of cancer and improve outcomes.
Incendia’s most advanced investigational therapeutic is PRTH-101, a novel therapeutic antibody that binds to and inhibits Discoidin Domain Receptor 1 (DDR1), an element of the TME that is highly expressed by cancer cells in multiple solid tumor types. The Company is currently recruiting patients into a Phase 1c clinical trial with PRTH-101 for the treatment of patients with advanced solid tumors (thymic carcinoma).
Company Details
- Employees
- 37
- Address
- 1 Canal Park,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.incendiatx.com
- HQ
- Cambridge, Massachusetts
Incendia Therapeutics Questions
Incendia Therapeutics's website is http://www.incendiatx.com
Incendia Therapeutics's LinkedIn profile is https://www.linkedin.com/company/incendiatherapeutics
Incendia Therapeutics has
37 employees.
View email and phone details for 37
employees at Incendia Therapeutics.
Incendia Therapeutics's industry is
Biotechnology Research
Incendia Therapeutics's top competitors are
Nona Biosciences,
Marengo Therapeutics,
Vivtex,
Qld Biotherapeutics Inc,
1910 Genetics,
Kytopen,
Manifold Bio,
Stellaromics Inc.,
Pledge Therapeutics,
Scismic.
Incendia Therapeutics's categories are Biotechnology Research
